UNSPSC 51272105: Hydroxytetracaine

This classification denotes an anesthetic agent with the molecular formula C15H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A96H4311N, chemically known as 4-(butylamino)-2-hydroxy-benzoic acid, 2-(dimethylino)ethyl ester (9ci) but generally known as hydroxytetracaine, which bears US NIH Compound Identifier 71630. European Medicines Agency schedules Hydroxytetracaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08086MIG.

UNSPSC 51272105 Hydroxytetracaine is a Commodity code, but the recent state and local opportunities posted under it do not reflect procurement of this specific local anesthetic agent. Instead, the code's recent activity includes broader pharmaceutical and medical supply procurement: emergency response medications (naloxone), drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory direct-to-manufacturer prescription programs. State and local issuing bodies soliciting under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving state agencies and local government facilities across multiple states including Oregon). The procurement activity signals that state and local governments use this code's taxonomy to source emergency medical supplies, generic pharmaceuticals distributed through authorized wholesalers, and prescription fulfillment infrastructure rather than hydroxytetracaine as a standalone pharmaceutical line item.

Geographic activity centers on Florida, Texas, and the Upper Midwest and West (Minnesota, Oregon) based on recent postings. Representative opportunities include Seminole County's IFB60459723LAS (issued June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and fixed-fee pricing under a two-year contract with optional one-year renewal; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products sold through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and mandatory cGMP and Drug Supply Chain Security Act compliance; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows limited relevance to hydroxytetracaine specifically and greater relevance to emergency medications, generic pharmaceuticals, and prescription program infrastructure.